Schizandrin A promotes apoptosis in prostate cancer by inducing ROS-mediated endoplasmic reticulum stress and JNK...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Prostate cancer (PCa) is a prevalent malignancy in males with limited treatment options.
• Schizandrin A (SchA), a lignan from Schisandra chinensis, exhibits biological activity.
• Investigating SchA's role in PCa progression is crucial for developing new therapies.

Purpose of the Study:

• To evaluate the anti-cancer effects of Schizandrin A (SchA) on prostate cancer (PCa) cells.
• To elucidate the underlying molecular mechanisms of SchA's action in PCa.
• To assess the therapeutic potential of SchA in preclinical models.

Main Methods:

• In vitro studies involved treating PCa cells (VCap, DU145) with SchA.
• Assays included MTT, colony formation, DCFH-DA, western blotting, TUNEL, and flow cytometry (cell cycle, apoptosis, JC-1).
• In vivo efficacy was evaluated using a tumor xenograft model in nude mice.

Main Results:

• SchA significantly suppressed PCa cell proliferation and induced G2/M cell cycle arrest.
• SchA promoted apoptosis by enhancing reactive oxygen species (ROS) generation and endoplasmic reticulum (ER) stress.
• Activation of JNK signaling pathway was observed, contributing to PCa cell apoptosis and suppressed tumor growth in vivo.

Conclusions:

• Schizandrin A (SchA) demonstrates potent anti-prostate cancer activity.
• SchA induces cell cycle arrest and apoptosis via ROS-mediated ER stress and JNK MAPK signaling.
• SchA presents a promising natural compound for prostate cancer treatment.